Insider Selling: Phreesia, Inc. (NYSE:PHR) General Counsel Sells 8,426 Shares of Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 8,426 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total value of $230,114.06. Following the transaction, the general counsel now owns 146,126 shares of the company’s stock, valued at approximately $3,990,701.06. This trade represents a 5.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Phreesia Stock Performance

Shares of PHR opened at $27.29 on Thursday. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The business’s 50-day moving average is $23.77 and its 200-day moving average is $22.94. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $29.16.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same quarter in the prior year, the business earned ($0.58) EPS. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. On average, analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Trading of Phreesia

Several large investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C bought a new position in shares of Phreesia during the 2nd quarter valued at $4,078,000. Champlain Investment Partners LLC raised its holdings in Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after buying an additional 97,847 shares in the last quarter. Sei Investments Co. lifted its position in shares of Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after buying an additional 95,058 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Phreesia by 56.3% during the 2nd quarter. Squarepoint Ops LLC now owns 250,396 shares of the company’s stock worth $5,308,000 after acquiring an additional 90,215 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock valued at $30,256,000 after acquiring an additional 88,517 shares during the last quarter. 92.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. KeyCorp upped their price objective on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Truist Financial lifted their target price on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Robert W. Baird dropped their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Finally, Citigroup raised their price objective on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia currently has a consensus rating of “Buy” and a consensus target price of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.